Wells Fargo's David Maris says Mallinckrodt (NYSE:MNK) is exploring all strategic options, including going private. He informed clients in a note after meeting with the company last week.
Shares have been in a steady downtrend for almost a year. Short seller Citron Research has jumped on the bandwagon saying sales and margins will be under pressure as the price of Acthar gel drops.
Shares are up 2% premarket on average volume.
Now read: Avoid Mallinckrodt Into Earnings »
Subscribe for full text news in your inbox